- Home
- AFRI vs VNDA Comparison
AFRI vs VNDA Comparison
Compare AFRI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- VNDA
- Stock Information
- Founded
- AFRI 1943
- VNDA 2002
- Country
- AFRI Gibraltar
- VNDA United States
- Employees
- AFRI N/A
- VNDA N/A
- Industry
- AFRI Packaged Foods
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- VNDA Health Care
- Exchange
- AFRI Nasdaq
- VNDA Nasdaq
- Market Cap
- AFRI 231.2M
- VNDA 237.9M
- IPO Year
- AFRI N/A
- VNDA 2006
- Fundamental
- Price
- AFRI $8.55
- VNDA $4.33
- Analyst Decision
- AFRI
- VNDA Strong Buy
- Analyst Count
- AFRI 0
- VNDA 2
- Target Price
- AFRI N/A
- VNDA $16.50
- AVG Volume (30 Days)
- AFRI 12.1K
- VNDA 754.6K
- Earning Date
- AFRI 04-30-2025
- VNDA 05-07-2025
- Dividend Yield
- AFRI N/A
- VNDA N/A
- EPS Growth
- AFRI N/A
- VNDA N/A
- EPS
- AFRI N/A
- VNDA N/A
- Revenue
- AFRI $325,098,000.00
- VNDA $198,772,000.00
- Revenue This Year
- AFRI N/A
- VNDA $14.36
- Revenue Next Year
- AFRI N/A
- VNDA $44.53
- P/E Ratio
- AFRI N/A
- VNDA N/A
- Revenue Growth
- AFRI 15.94
- VNDA 3.18
- 52 Week Low
- AFRI $8.05
- VNDA $3.85
- 52 Week High
- AFRI $12.00
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- AFRI 46.07
- VNDA 43.42
- Support Level
- AFRI $8.50
- VNDA $4.27
- Resistance Level
- AFRI $9.10
- VNDA $4.46
- Average True Range (ATR)
- AFRI 0.42
- VNDA 0.22
- MACD
- AFRI 0.03
- VNDA 0.01
- Stochastic Oscillator
- AFRI 47.12
- VNDA 54.55
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.